• TEXT SIZE

Results with ENBREL in
Ankylosing Spondylitis (AS)

In 2003, ENBREL became the first biologic approved as a treatment option for ankylosing spondylitis (AS).

Proven results

In medical studies, ENBREL has been shown to significantly reduce the symptoms of ankylosing spondylitis. Many AS patients using ENBREL experienced a greater reduction in back pain (including nighttime pain), inflammation, and morning stiffness; improved spinal mobility; and an improvement in the ability to do everyday tasks.

Your results may vary. Because ENBREL works on the immune system, it can lower the ability of your immune system to fight infections and may raise other safety concerns. Please see Full Prescribing Information, Important Safety Information, and Medication Guide for complete details about ENBREL.

Indication

Supportive data


Diagnosed with AS?

Sign up today for more information about ankylosing spondylitis and ENBREL.

SIGN UP TODAY